These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 20887676)

  • 1. The role of cancer stem cells (CD133(+)) in malignant gliomas.
    Cho DY; Lin SZ; Yang WK; Hsu DM; Lin HL; Lee HC; Lee WY; Chiu SC
    Cell Transplant; 2011; 20(1):121-5. PubMed ID: 20887676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
    Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
    Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
    Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
    Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
    Song WC; Fei XF; Dong J
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies.
    Denysenko T; Gennero L; Roos MA; Melcarne A; Juenemann C; Faccani G; Morra I; Cavallo G; Reguzzi S; Pescarmona G; Ponzetto A
    Cell Biochem Funct; 2010 Jul; 28(5):343-51. PubMed ID: 20535838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
    Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
    Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNA expression profile of colon cancer stem cells compared to non-stem cells using the SW1116 cell line.
    Fang Y; Xiang J; Chen Z; Gu X; Li Z; Tang F; Zhou Z
    Oncol Rep; 2012 Dec; 28(6):2115-24. PubMed ID: 23007737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biological characteristics of glioma stem cells in human glioma cell line SHG44.
    Liu L; Li WY; Chen Q; Zheng JK; Yang LY
    Mol Med Rep; 2012 Feb; 5(2):552-8. PubMed ID: 22038279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into the complex regulation of CD133 in glioma.
    Campos B; Herold-Mende CC
    Int J Cancer; 2011 Feb; 128(3):501-10. PubMed ID: 20853315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
    Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
    PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
    Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
    Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of stemness-related molecules in neuroblastoma.
    Kamijo T
    Pediatr Res; 2012 Apr; 71(4 Pt 2):511-5. PubMed ID: 22430387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
    Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
    Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).
    Choijamts B; Jimi S; Kondo T; Naganuma Y; Matsumoto T; Kuroki M; Iwasaki H; Emoto M
    Stem Cells; 2011 Oct; 29(10):1485-95. PubMed ID: 21919130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice.
    Dou J; He XF; Cao WH; Zhao FS; Wang XY; Liu YR; Wang J
    Cell Mol Biol (Noisy-le-grand); 2013 Oct; Suppl 59():OL1861-8. PubMed ID: 24120113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
    He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM
    Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.